Dermapharm Holding SE (DMP.DE)

EUR 38.15

(0.39%)

Total Liabilities Summary of Dermapharm Holding SE

Dermapharm Holding SE's latest annual total liabilities in 2023 was 1.62 Billion EUR , up 84.79% from previous year.
Dermapharm Holding SE's latest quarterly total liabilities in 2024 Q2 was 1.65 Billion EUR , up 4.09% from previous quarter.
Dermapharm Holding SE reported annual total liabilities of 880.34 Million EUR in 2022, down -2.95% from previous year.
Dermapharm Holding SE reported annual total liabilities of 907.13 Million EUR in 2021, up 0.81% from previous year.
Dermapharm Holding SE reported quarterly total liabilities of 1.65 Billion EUR for 2024 Q2, up 4.09% from previous quarter.
Dermapharm Holding SE reported quarterly total liabilities of 1.59 Billion EUR for 2023 Q2, up 0.33% from previous quarter.

Annual Total Liabilities Chart of Dermapharm Holding SE (2023 - 2013)

Historical Annual Total Liabilities of Dermapharm Holding SE (2023 - 2013)

Year	Total Liabilities	Total Liabilities Growth
2023	1.62 Billion EUR	84.79%
2022	880.34 Million EUR	-2.95%
2021	907.13 Million EUR	0.81%
2020	899.81 Million EUR	18.34%
2019	760.38 Million EUR	69.54%
2018	448.49 Million EUR	31.29%
2017	341.61 Million EUR	36.16%
2016	250.89 Million EUR	-0.53%
2015	252.22 Million EUR	-14.96%
2014	296.58 Million EUR	-3.9%
2013	308.61 Million EUR	0.0%

Year	Total Liabilities	Total Liabilities Growth
2024 Q1	1.58 Billion EUR	-2.52%
2024 Q2	1.65 Billion EUR	4.09%
2023 Q2	1.59 Billion EUR	0.33%
2023 Q3	1.61 Billion EUR	1.38%
2023 FY	1.62 Billion EUR	84.79%
2023 Q1	1.58 Billion EUR	80.27%
2023 Q4	1.62 Billion EUR	0.79%
2022 Q2	961.43 Million EUR	3.94%
2022 Q4	880.34 Million EUR	-6.93%
2022 FY	880.34 Million EUR	-2.95%
2022 Q1	924.95 Million EUR	1.96%
2022 Q3	945.87 Million EUR	-1.62%
2021 Q1	915.91 Million EUR	1.79%
2021 FY	907.13 Million EUR	0.81%
2021 Q4	907.13 Million EUR	-0.81%
2021 Q3	914.54 Million EUR	0.19%
2021 Q2	912.82 Million EUR	-0.34%
2020 Q2	920.98 Million EUR	18.57%
2020 Q4	899.81 Million EUR	-1.96%
2020 Q1	776.74 Million EUR	2.15%
2020 Q3	917.81 Million EUR	-0.34%
2020 FY	899.81 Million EUR	18.34%
2019 Q3	750.31 Million EUR	6.33%
2019 FY	760.38 Million EUR	69.54%
2019 Q1	685.83 Million EUR	52.92%
2019 Q2	705.62 Million EUR	2.88%
2019 Q4	760.38 Million EUR	1.34%
2018 Q2	471.06 Million EUR	-1.72%
2018 FY	448.49 Million EUR	31.29%
2018 Q4	448.49 Million EUR	0.17%
2018 Q3	447.73 Million EUR	-4.95%
2018 Q1	479.32 Million EUR	40.31%
2017 Q4	341.61 Million EUR	-4.88%
2017 Q3	359.15 Million EUR	0.0%
2017 Q1	- EUR	-100.0%
2017 FY	341.61 Million EUR	36.16%
2016 FY	250.89 Million EUR	-0.53%
2016 Q4	250.89 Million EUR	0.0%
2015 FY	252.22 Million EUR	-14.96%
2014 FY	296.58 Million EUR	-3.9%
2013 FY	308.61 Million EUR	0.0%

Peer Total Liabilities Comparison of Dermapharm Holding SE

Name	Total Liabilities	Total Liabilities Difference
MPH Health Care AG	15.38 Million EUR	-10472.732%
Apontis Pharma AG	27.2 Million EUR	-5880.779%
Evotec SE	1.17 Billion EUR	-37.962%
MERCK Kommanditgesellschaft auf Aktien	22.36 Billion EUR	92.727%
PharmaSGP Holding SE	91.54 Million EUR	-1677.019%
SynBiotic SE	19.59 Million EUR	-8203.684%